The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Government and Industry Collaboration in AIDS Drug Development: Summary of a Workshop Held on May 6, 1994
10:45
Impediments to Collaboration on HIV Drug and VaccineDevelopment: Defining the Issues
Discussion Leader: Patrick Gage, Chief Operating Officer,Genetics Institute, Inc.
Commentary from a Government/NIH Perspective
Bruce Chabner, Director, Division of Cancer Treatment,National Cancer Institute
A View from the Pharmaceutical Industry
Stephen Carter, Senior Vice President, World WideClinical Research & Development, Bristol-Myers SquibbPharmaceutical Research Institute
Practical Implications of Rules Governing Intellectual Property Developed from Collaborative Relationships
Harold Edgar, Professor of Law, Columbia UniversitySchool of Law
11:30
Discussion
1:00
Lunch
2:00
Overcoming Obstacles to Collaboration and Promoting HIVDrug and Vaccine Development: Proposals for Resolution
Discussion Leader: Martin Delaney, Founding Director, ProjectInform
Industry Perspective
David Barry, Group Director, Research, Development andMedical Affairs, The Wellcome Research Laboratories
Government/NIH Perspective
Anthony Fauci, Director, National Institute of Allergy andInfectious Diseases
Congressional/Legislative Response
Timothy Westmoreland, Counsel, Subcommittee on Healthand the Environment, U.S. House of Representatives
